COVID-19 is a global epidemic caused by severe acute respiratory syndrome coronavirus 2 infection. However, the understanding of long-term respiratory diseases in COVID-19 survivors remains limited.To identify the incidence and risk factors of post-COVID-19 pulmonary fibrosis, a comprehensive search of relevant studies published before the 2nd of April 2023 in PubMed, Embase, Web of Science, and Cochrane Library was conducted, and 18 papers were eligible for this study.  The existing literature evidence showed that about 36.4% of COVID-19 survivors may have developed pulmonary fibrosis, and people with advanced age, male, hypertension, diabetes, glucocorticoid therapy, mechanical ventilation, prolonged hospitalization, and severe COVID-19 are at higher risk of developing this sequela.

Jing Yang, Huifen Feng, Mingzhu Wang, Shan Zheng, Ning Ai. Prevalence and Risk Factors of Post-COVID-19 Pulmonary Fibrosis: A Meta-analysis. Frontiers in Medical Science Research (2023) Vol. 5, Issue 12: 36-42. https://doi.org/10.25236/FMSR.2023.051204.

[1] Hirawat R, Jain N, Saifi M A, et al. Lung fibrosis: Post-COVID-19 complications and evidences[J]. International Immunopharmacology, 2023, 116: 109418.

[2] Rai D K, Sharma P, Kumar R. Post covid 19 pulmonary fibrosis. Is it real threat?[J]. The Indian Journal of Tuberculosis, 2021, 68(3): 330-333.

[3] Yoon H Y, Uh S T. Post–Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention [J]. Tuberculosis and Respiratory Diseases, 2022, 85(4): 320-331.

[4] Mylvaganam R J, Bailey J I, Sznajder J I, et al. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection[J]. European Respiratory Review, 2021, 30(162).

[5] Soriano J B, Murthy S, Marshall J C, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus[J]. The Lancet. Infectious Diseases, 2022, 22(4): e102-e107.

[6] Wu X, Dong D, Ma D. Thin-Section Computed Tomography Manifestations During Convalescence and Long-Term Follow-Up of Patients with Severe Acute Respiratory Syndrome (SARS)[J]. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 2016, 22: 2793-2799.

[7] Aul D R, Gates D J, Draper D A, et al. Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis[J]. Respiratory Medicine, 2021, 188: 106602.

[8] Bocchino M, Lieto R, Romano F, et al. Chest CT–based Assessment of 1-year Outcomes after Moderate COVID-19 Pneumonia[J]. Radiology, 2022, 305(2): 479-485.

[9] Caruso D, Guido G, Zerunian M, et al. Postacute Sequelae of COVID-19 Pneumonia: 6-month Chest CT Follow-up[J]. Radiology, 2021: 210834.

[10] Han X, Fan Y, Alwalid O, et al. Six-Month Follow-up Chest CT findings after Severe COVID-19 Pneumonia[J]. Radiology, 2021: 203153.

[11] Lee I, Kim J, Yeo Y, et al. Prognostic Factors for Pulmonary Fibrosis Following Pneumonia in Patients with COVID-19: A Prospective Study[J]. Journal of Clinical Medicine, 2022, 11(19): 5913.

[12] Li D, Liao X, Liu Z, et al. Healthy outcomes of patients with COVID-19 two years after the infection: a prospective cohort study[J]. Emerging Microbes & Infections, 2022, 11(1): 2680-2688.

[13] Li X, Shen C, Wang L, et al. Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia: a cohort study[J]. Respiratory Research, 2021, 22: 203.

[14] Liao T, Meng D, Xiong L, et al. Long-Term Effects of COVID-19 on Health Care Workers 1-Year Post-Discharge in Wuhan[J]. Infectious Diseases and Therapy, 2022, 11(1): 145-163.

[15] Liu M, Lv F, Huang Y, et al. Follow-Up Study of the Chest CT Characteristics of COVID-19 Survivors Seven Months After Recovery[J]. Frontiers in Medicine, 2021, 8: 636298.

[16] Ribeiro Carvalho C R, Lamas C A, Chate R C, et al. Long-term respiratory follow-up of ICU hospitalized COVID-19 patients: Prospective cohort study[J]. PLOS ONE, 2023, 18(1): e0280567.

[17] Robey R C, Kemp K, Hayton P, et al. Pulmonary Sequelae at 4 Months After COVID-19 Infection: A Single-Centre Experience of a COVID Follow-Up Service[J]. Advances in Therapy, 2021, 38(8): 4505-4519.

[18] Tarraso J, Safont B, Carbonell-Asins J A, et al. Lung function and radiological findings 1 year after COVID-19: a prospective follow-up[J]. Respiratory Research, 2022, 23: 242.

[19] van Gassel R J J, Bels J L M, Raafs A, et al. High Prevalence of Pulmonary Sequelae at 3 Months after Hospital Discharge in Mechanically Ventilated Survivors of COVID-19[J]. American Journal of Respiratory and Critical Care Medicine, 2021, 203(3): 371-374.

[20] Zhao Y, Yang C, An X, et al. Follow-up study on COVID-19 survivors one year after discharge from hospital[J]. International Journal of Infectious Diseases, 2021, 112: 173-182.

[21] Zhou F, Tao M, Shang L, et al. Assessment of Sequelae of COVID-19 Nearly 1 Year After Diagnosis[J]. Frontiers in Medicine, 2021, 8: 717194.

[22] Li F, Deng J, Song Y, et al. Pulmonary fibrosis in patients with COVID-19: A retrospective study[J]. Frontiers in Cellular and Infection Microbiology, 2022, 12: 1013526.

[23] Marvisi M, Ferrozzi F, Balzarini L, et al. First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution[J]. International Journal of Infectious Diseases, 2020, 99: 485-488.

[24] Yang Z L, Chen C, Huang L, et al. Fibrotic Changes Depicted by Thin-Section CT in Patients With COVID-19 at the Early Recovery Stage: Preliminary Experience[J]. Frontiers in Medicine, 2020, 7: 605088.

[25] Das K M, Lee E Y, Singh R, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery[J]. The Indian Journal of Radiology & Imaging, 2017, 27(3): 342-349.

[26] Zhang P, Li J, Liu H, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study[J]. Bone Research, 2020, 8: 8.

[27] Jaillon S, Berthenet K, Garlanda C. Sexual Dimorphism in Innate Immunity[J]. Clinical Reviews in Allergy & Immunology, 2019, 56(3): 308-321.

[28] Villar J, Cabrera N E, Valladares F, et al. Activation of the Wnt/β-Catenin Signaling Pathway by Mechanical Ventilation Is Associated with Ventilator-Induced Pulmonary Fibrosis in Healthy Lungs[J]. PLoS ONE, 2011, 6(9): e23914.

[29] Cabrera-Benítez N E, Parotto M, Post M, et al. Mechanical stress induces lung fibrosis by epithelial-mesenchymal transition (EMT)[J]. Critical care medicine, 2012, 40(2): 510-517.

[30] Adegunsoye A, Baccile R, Best T J, et al. Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United States[J]. Lancet Regional Health - Americas, 2023, 25: 100566.

[31] Myall K J, Mukherjee B, Castanheira A M, et al. Persistent Post–COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment[J]. Annals of the American Thoracic Society, 2021, 18(5): 799.

[32] Stockman L J, Bellamy R, Garner P. SARS: Systematic Review of Treatment Effects[J]. PLoS Medicine, 2006, 3(9): e343.

[33] Russell C D, Millar J E, Baillie J K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury[J]. The Lancet, 2020, 395(10223): 473-475.